SeaStar Medical Q4 2025 revenue $420K; net loss narrows to $2.9M; cash grows to $12M

SeaStar Medical Holding Corp

Net revenue Q4 2025 $420K (vs $67K Q4 2024); full year $1.2M (vs $135K).
Net loss Q4 2025 $2.9M ($0.80/share) vs $4.4M ($8.98/share) Q4 2024; cash $12.0M (up from $1.8M).
QUELIMMUNE expanded to 16 children's hospitals; SAVE Registry enrollment completed (50 patients).
NEUTRALIZE-AKI trial >50% enrolled (181/339); modular PMA submission for adult AKI initiated.
Guides 2026 net product revenue ~$2M; plans to add 15 more hospital sites.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SeaStar Medical Holding Corp reported three months and year ended December 31, 2025 results: revenue approximately $2 million in net product revenue in 2026.

Period: three months and year ended December 31, 2025
Revenue: approximately $2 million in net product revenue in 2026
Result: reported results

Exact text from the filing

On March 25, 2026, SeaStar Medical Holding Corp. (the "Company") issued a press release announcing its financial condition and results of operations for the three and twelve months ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0001437749-26-009780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.